FT Options’s Clovis Oncology, Inc. CLVS Stock Holding History

FT Options’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$1.79M	Sell	21,787 -19,713	-48%	-$1.56M	2.71%	6
2017 Q2	$3.89M	Buy	41,500 +37,679	+986%	+$2.31M	6.69%	1
2017 Q1	$243K	Buy	+3,821	New	+$232K	0.32%	69
2016 Q4	–	Sell	-71,091	Closed	-$2.56M	–	407
2016 Q3	$2.56M	Buy	71,091 +65,901	+1,270%	+$1.41M	2.03%	9
2016 Q2	$71K	Sell	5,190 -2,620	-34%	-$38.3K	0.06%	179
2016 Q1	$150K	Sell	7,810 -1,850	-19%	-$39.2K	0.16%	102
2015 Q4	$338K	Buy	+9,660	New	+$623K	0.25%	73

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FT Options's CLVS Position: Q3 2017 in Review

FT Options reduced its Clovis Oncology, Inc. (CLVS) stake by 48% in Q3 2017, selling an estimated $1.56M and leaving 21,787 shares worth $1.79M. The position accounts for 2.71% of the portfolio, ranked #6.

FT Options first reported a position in CLVS in Q4 2015 and has held it in 7 quarters since. The position peaked at $3.89M in Q2 2017. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

FT Options held 21,787 shares of Clovis Oncology, Inc. worth $1.79M as of Q3 2017.
FT Options sold 19,713 Clovis Oncology, Inc. shares in Q3 2017, an estimated $1.56M.
Clovis Oncology, Inc. made up 2.71% of FT Options's portfolio in Q3 2017, its #6 holding.
FT Options first reported a position in Clovis Oncology, Inc. in Q4 2015 and has held it in 7 quarters since.
FT Options's Clovis Oncology, Inc. position peaked at $3.89M in Q2 2017.
255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.